MS
FDA Issues Warning About Anaphylaxis Risk From MS Drug
The FDA issued a warning about the risk for anaphylaxis, which could lead to hospitalizations and deaths, ...
JANUARY 24, 2025
People With MS Disproportionately at Risk for Hospitalization and Death From COVID-19
Even after receiving at least three COVID-19 vaccinations, people with MS had an almost six times greater risk for ...
MAY 1, 2024
FDA Approves Tyruko for Relapsing MS
The FDA approved Tyruko, the first biosimilar to treat multiple sclerosis.
AUGUST 25, 2023
Glatiramer Acetate for Breastfeeding Mothers With MS May Be Appropriate
New mothers suffering from relapsing multiple sclerosis (RMS) might be able to continue disease-modifying treatment ...
JULY 13, 2022
Epstein-Barr Virus May Be Leading Cause of MS
Establishing a causal relationship between the virus and disease has been difficult because EBV infects ...
JANUARY 18, 2022
Pandemic Changed Clinical Practice for MS
A survey of U.S. multiple sclerosis specialists showed the COVID-19 pandemic created major changes in how they ...
MAY 12, 2021
FDA Approves New Oral Mavenclad for MS
Following the administration of two treatment courses, additional courses of cladribine are not to be administered ...
APRIL 1, 2019
FDA Approves Oral Drug for Relapsing Forms of MS
Mayzent is the first and only treatment specifically approved for patients with active secondary progressive ...
MARCH 27, 2019
FDA Granted a New Indication for Gilenya to Treat RMS in Children
Gilenya is the first DMT indicated for children and adolescents with relapsing forms of multiple sclerosis.
MAY 16, 2018
Ocrelizumab Gets Breakthrough Designation for Progressive MS
The FDA has granted breakthrough therapy designation for Genentech’s drug ocrelizumab in patients with ...
FEBRUARY 26, 2016
